New AI drug discovery tie-ups and projects: Ono–Aitia, Hiro, MND, JapanFold

Aug 31, 2026 · Issue 5 · 8 sources, 8 articles

Ono Pharma is working with Aitia's Gemini Digital Twin platform on neurological diseases, while Hiro and Differentia Biotech are deploying AI-based trial simulation. Separately, a company designed a drug candidate with help from ChatGPT and Gemini, and JapanFold keeps open-source computations inside Japan.

Who is affected and how

pharmaceuticals

The partnerships and local data-handling arrangements offer examples for procurement and partner-selection decisions.

Sources

• Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases - BioSpacebiospace.com · Sep 2, 2026
• Ono Pharma Partners With Aitia on Causal AI Drug Discovery - cGxP.wirecgxpwire.com · Sep 3, 2026
• This company designed a drug candidate with help from ChatGPT and Gemini – Carbon Chemistcarbonchemist.com · Aug 31, 2026
• This company designed a drug candidate with help from ChatGPT and Geminicen.acs.org · Aug 31, 2026 · magyar
• Hiro & Differentia Biotech Deploy Trial AI Simulationclinicaltrialsarena.com · Aug 31, 2026
• AI speeds MND drug discovery with algorithm-led analysisleadmonitor.ai · Aug 31, 2026
• JapanFold Keeps Open-Source Drug Discovery Computations Inside Japan – Unite.AIunite.ai · Sep 2, 2026
• ai& and Tenstorrent Launch JapanFold, Bringing Open-Source, Sovereign Drug Discovery to Japaneinpresswire.com · Sep 3, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.